Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Bioequivalence study
Status
Ended
Participants planned
36
Countries
1
Sites
1
not applicable (submitted trial is a bioequivalence study)
Key facts
- Sponsor
- Ewopharma AG
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Virus Diseases [C02]
- Trial duration
- 24 Oct 2024 → 21 Nov 2024
- Decision date (initial)
- 2024-09-06
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
not applicable (submitted trial is a bioequivalence study)
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 21.1 | PT | 10068724 | Antiviral treatment | 100000004865 |
| 20.1 | PT | 10007877 | Cell-mediated immune deficiency | 100000004870 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Ewopharma AG
- Sponsor organisation
- Ewopharma AG
- Address
- Vordergasse 43
- City
- Schaffhausen
- Postcode
- 8200
- Country
- Switzerland
Scientific contact point
- Organisation
- Ewopharma AG
- Contact name
- Suzanne Curran
Public contact point
- Organisation
- Ewopharma AG
- Contact name
- Suzanne Curran
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Czechia | Ended | 36 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Quinta-Analytica s.r.o.
Clinic, Umelecka 305/1, Moravska Ostrava, Moravska Ostrava A Privoz
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Czechia | 2024-10-24 | 2024-11-21 | 2024-10-24 | 2024-11-13 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-08-09 | Czechia | Acceptable 2024-09-03
|
2024-09-06 |